Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world insights into patients with advanced NSCLC and MET alterations.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2021

Bittoni Marisa, Yang James Chih-Hsin, Shih Jin-Yuan, Peled Nir, Smit Egbert F, Camidge D Ross, Arasada Rajeswara Rao, Oksen Dina, Boutmy Emmanuelle, Stroh Christopher, Johne Andreas, Carbone David P, Paik Paul K

Abstract excerpt

OBJECTIVES: To describe characteristics, treatment and outcomes of non-small cell lung cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET amplification [METamp]) in real-world clinical care. METHODS: This non-interventional cohort study used real-world data extracted from electronic medical records from academic oncology sites in Israel, The Netherlands, Taiwan, and the USA....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34320421
DOI: 10.1016/j.lungcan.2021.06.015
PMCID: PMC9345068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world insights into patients with advanced NSCLC and MET alterations.PMID 34320421Read ↗

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.Semantic proximity Read ↗

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationSemantic proximity Read ↗

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.